Net Margin | 2026-04-23 | Quality Score: 94/100
Expert US stock fundamental screening criteria and quality metrics to identify companies with durable competitive advantages. Our fundamental analysis goes beyond simple ratios to understand the true drivers of long-term business value.
DaVita Inc., a leading U.S. kidney care and dialysis services provider with a $10 billion market capitalization, is set to release its fiscal Q1 2026 financial results post-market on May 11, 2026. Sell-side analysts forecast 20.5% year-over-year (YoY) adjusted earnings per share (EPS) growth to $2.4
Live News
As of April 22, 2026, consensus estimates compiled by Zacks and Morningstar peg DaVita’s Q1 2026 adjusted EPS at $2.41, representing a 20.5% rise from the $2.00 per share reported in the year-ago quarter. The Denver-based firm has beaten Wall Street earnings estimates in three of the last four reporting periods, with a single miss in Q2 2025 tied to temporary regulatory reimbursement adjustments. For full-year fiscal 2026, analysts project adjusted EPS of $14.16, implying 31.4% YoY growth from 2
DaVita Inc. (XLV) - Q1 2026 Earnings Preview: Balanced Growth Trajectory Amid Sector CrosswindsMany investors adopt a risk-adjusted approach to trading, weighing potential returns against the likelihood of loss. Understanding volatility, beta, and historical performance helps them optimize strategies while maintaining portfolio stability under different market conditions.Effective risk management is a cornerstone of sustainable investing. Professionals emphasize the importance of clearly defined stop-loss levels, portfolio diversification, and scenario planning. By integrating quantitative analysis with qualitative judgment, investors can limit downside exposure while positioning themselves for potential upside.DaVita Inc. (XLV) - Q1 2026 Earnings Preview: Balanced Growth Trajectory Amid Sector CrosswindsAccess to multiple indicators helps confirm signals and reduce false positives. Traders often look for alignment between different metrics before acting.
Key Highlights
DaVita’s Q4 2025 results, released on February 2, 2026, delivered a material upside to consensus estimates, with adjusted EPS of $3.40 and total revenue of $3.6 billion. The strong performance was driven by 36% YoY adjusted EPS growth, 10% YoY revenue expansion, supported by higher government and commercial reimbursement rates, an optimized care portfolio mix, elevated seasonal flu vaccine administration demand, and a 3% YoY rise in patient service revenue per treatment to $422.60. Shares rallie
DaVita Inc. (XLV) - Q1 2026 Earnings Preview: Balanced Growth Trajectory Amid Sector CrosswindsInvestor psychology plays a pivotal role in market outcomes. Herd behavior, overconfidence, and loss aversion often drive price swings that deviate from fundamental values. Recognizing these behavioral patterns allows experienced traders to capitalize on mispricings while maintaining a disciplined approach.Using multiple analysis tools enhances confidence in decisions. Relying on both technical charts and fundamental insights reduces the chance of acting on incomplete or misleading information.DaVita Inc. (XLV) - Q1 2026 Earnings Preview: Balanced Growth Trajectory Amid Sector CrosswindsContinuous learning is vital in financial markets. Investors who adapt to new tools, evolving strategies, and changing global conditions are often more successful than those who rely on static approaches.
Expert Insights
As a core defensive healthcare services constituent of the XLV ETF, DaVita’s upcoming Q1 print will serve as a key barometer for both company-specific execution and broader sector trends, including reimbursement stability, labor cost inflation, and chronic care demand trends. The stock’s 220 basis point outperformance relative to the XLV over the past 12 months reflects investor pricing of its above-sector earnings growth outlook, while its underperformance relative to the S&P 500 aligns with the broader market’s 2025-early 2026 preference for high-growth tech and consumer discretionary assets. For the upcoming Q1 release, market participants will prioritize three core metrics to gauge DaVita’s forward trajectory. First, sequential and YoY changes in per-treatment patient revenue, to confirm if the 3% gain recorded in Q4 2025 was sustained amid ongoing wage and medical supply cost pressures that have compressed margins across the healthcare services sector. Second, management commentary on 2026 reimbursement rate stability, as any downward adjustment to Medicare dialysis reimbursement rates would pose a material downside risk to full-year earnings guidance, given that government payers account for nearly 70% of DaVita’s total revenue. Third, updates on home dialysis adoption rates, which carry 150-200 basis points higher margins than traditional in-center treatments and are a core pillar of the firm’s long-term margin expansion strategy. The consensus "Hold" rating and limited implied upside from current levels reflect balanced risk-reward dynamics for DaVita at its current valuation of 10.7x forward 2026 adjusted EPS, a 12% premium to the average XLV healthcare services peer valuation. On the upside, a Q1 earnings beat paired with an upward revision to full-year guidance above the current $13.60-$15.00 range could drive a re-rating toward the high end of analyst target ranges at $172 per share. On the downside, a miss on per-treatment revenue or a downward adjustment to reimbursement outlooks could push shares toward the low end of analyst targets at $129 per share. For XLV ETF investors, DaVita’s results will also offer actionable insight into cost and revenue trends that impact a broad swathe of non-biopharma healthcare constituents in the fund, making the print a high-impact event for sector allocation decisions. (Word count: 1182)
DaVita Inc. (XLV) - Q1 2026 Earnings Preview: Balanced Growth Trajectory Amid Sector CrosswindsThe interplay between short-term volatility and long-term trends requires careful evaluation. While day-to-day fluctuations may trigger emotional responses, seasoned professionals focus on underlying trends, aligning tactical trades with strategic portfolio objectives.Real-time analytics can improve intraday trading performance, allowing traders to identify breakout points, trend reversals, and momentum shifts. Using live feeds in combination with historical context ensures that decisions are both informed and timely.DaVita Inc. (XLV) - Q1 2026 Earnings Preview: Balanced Growth Trajectory Amid Sector CrosswindsHistorical volatility is often combined with live data to assess risk-adjusted returns. This provides a more complete picture of potential investment outcomes.
